
Patients randomised in the main period (N = 473, full analysis set)
RGB-14-P (n = 242, full analysis set)
Denosumab (n = 231, full analysis set)
Participants dosed (n = 242, safety analysis set)
Participants dosed (n = 231, safety analysis set)
Pharmacodynamic analysis set (n = 241)
Immunogenicity analysis set (n = 239)
Per-protocol analysis set (n = 240)
Pharmacodynamic analysis set (n = 229)
Immunogenicity analysis set (n = 228)
Per-protocol analysis set (n = 227)
Primary efficacy analyses
Percentage CfB in LS BMD at Week 52 (n = 242)
AUEC of the CfB in sCTX concentration until Week 26 (n = 241)
Primary efficacy analyses
Percentage change in LS BMD at Week 52 (n = 231)
AUEC of the CfB in sCTX concentration until Week 26 (n = 229)
Completed main period n = 225
Withdrawn in main period n = 17
Reason for end of treatment[a]
Withdrawal by participant n = 8
Adverse event n = 2
Lost to follow-up n = 3
Death n = 0
Protocol deviation n = 1
Other n = 2
Completed main period n = 211
Withdrawn in main period n = 20
Reason for end of treatment[a]
Withdrawal by participant n = 13
Adverse event n = 2
Lost to follow-up n = 0
Death n = 1
Protocol deviation n = 0
Other n = 2